1 Boushey, C.J., Beresford, S.A., Omenn, G.S. and Motulsky, A.G. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Journal of the American Medical Association, 274, 1049-57.
2 Nygard, O., Nordrehaug, J.E., Refsum, H., Ueland, P.M., Farstad, M. and Vollset SE. (1997). Plasma homocysteine levels and mortality in patients with coronary artery disease. New England Journal of Medicine, 337, 230-6.
3 Alfthan, G., Aro, A. and Gey K.F. (1997). Plasma homocysteine and cardiovascular disease mortality. Lancet, 349, 397.
4 Chambers, J.C., Obeid, O.A., Refsum, H. et al. (2000). Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet, 355, 523-7.
5 Stamler, J.S., Osborne, J.A., Jaraki, O. et al. (1993). Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. Journal of Clinical Investigation, 91, 308-18.
6 Dudman, N.P., Temple, S.E., Guo, X.W., Fu, W. and Perry, M.A. (1999). Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circulation Research, 84, 409-16.
7 Rodgers, G.M. and Kane, W.H. (1986). Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. Journal of Clinical Investigation, 77, 1909-16.
8 Lentz, S.R. and Sadler, J.E. (1991). Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. Journal of Clinical Investigation, 88, 1906-14.
9 Bellamy, M.F., McDowell, I.F., Ramsey, M.W. et al. (1998). Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation, 98, 1848-52.
10 Chambers, J.C., McGregor, A., Jean Marie, J., Obeid, O.A. and Kooner, J.S. (1999). Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation, 99, 1156-60.
11 Clarke, R. and Collins, R. (1998). Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. Journal ofCardiovascular Risk, 5, 249-55.
12 Bellamy, M.F., McDowell, I.F., Ramsey, M.W., Brownlee, M., Newcombe, R.G. and Lewis, M.J. (1999). Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. European Journal of Clinical Investigation, 29, 659-62.
13 Vermeulen, E.G., Stehouwer, C.D., Twisk, J.W. et al. (2000). Effect ofhomocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet, 355, 517-22.
Was this article helpful?